Litcius/Paper detail

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff, Yu Du, Jitong Lou, Sirel Gurbuz, Melissa K. Thomas, Mark L. Hartman, Axel Haupt, Zvonko Miličević, Tamer Coskun

2023The Lancet380 citationsDOI

Topics & Concepts

MedicineDulaglutidePlaceboType 2 diabetesExenatideMetforminInternal medicineGlucagon-like peptide 1 receptorDiabetes mellitusAgonistGlucagon-like peptide-1EndocrinologyReceptorAlternative medicinePathologyDiabetes Treatment and ManagementBariatric Surgery and OutcomesHyperglycemia and glycemic control in critically ill and hospitalized patients
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA | Litcius